Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coverage with Evidence Development: A Road to Accelerated Biomarker Adoption

This article was originally published in RPM Report

Executive Summary

Oncology biomarkers have the potential to significantly improve the quality and efficiency of health care, but their value hinges on whether payers will support the science. Private payer adoption of CMS' "coverage with evidence development" decisions could provide the appropriate regulatory and reimbursement framework.

You may also be interested in...



Dendreon vs. CMS: "Full Coverage" or the CED Solution?

A Medicare advisory committee brought few surprises for Dendreon’s prostate cancer therapy Provenge. Will CMS provide full coverage for Provenge or will it restrict use through coverage with evidence development?

Topics

UsernamePublicRestriction

Register

PS080231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel